21.04
0.77 (3.80%)
| Penutupan Terdahulu | 20.27 |
| Buka | 20.26 |
| Jumlah Dagangan | 122,386 |
| Purata Dagangan (3B) | 950,441 |
| Modal Pasaran | 641,006,080 |
| Harga / Pendapatan (P/E TTM) | 13.49 |
| Harga / Pendapatan (P/E Ke hadapan) | 48.78 |
| Harga / Jualan (P/S) | 2.90 |
| Harga / Buku (P/B) | 0.760 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | 1.96% |
| Margin Operasi (TTM) | 71.97% |
| EPS Cair (TTM) | -0.170 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 254,413.31% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.53% |
| Nisbah Semasa (MRQ) | 19.29 |
| Aliran Tunai Operasi (OCF TTM) | 44.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 30.29 M |
| Pulangan Atas Aset (ROA TTM) | -1.01% |
| Pulangan Atas Ekuiti (ROE TTM) | 0.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Keros Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.25 |
|
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.31% |
| % Dimiliki oleh Institusi | 109.35% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 27.00 (Oppenheimer, 28.33%) | Beli |
| Median | 21.00 (-0.19%) | |
| Rendah | 16.00 (Wedbush, -23.95%) | Pegang |
| Purata | 21.25 (1.00%) | |
| Jumlah | 2 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 17.01 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B of A Securities | 28 Nov 2025 | 19.00 (-9.70%) | Pegang | 17.48 |
| Oppenheimer | 12 Nov 2025 | 27.00 (28.33%) | Beli | 17.47 |
| Wells Fargo | 11 Nov 2025 | 23.00 (9.32%) | Beli | 16.90 |
| Wedbush | 06 Nov 2025 | 16.00 (-23.95%) | Pegang | 16.17 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Nov 2025 | Pengumuman | Keros Therapeutics Announces Final Results of Tender Offer |
| 19 Nov 2025 | Pengumuman | Keros Therapeutics Announces Preliminary Results of Tender Offer |
| 05 Nov 2025 | Pengumuman | Keros Therapeutics Reports Third Quarter 2025 Financial Results |
| 20 Oct 2025 | Pengumuman | Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares |
| 15 Oct 2025 | Pengumuman | Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital |
| 08 Sep 2025 | Pengumuman | Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |